Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $224K of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 8,305 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at $26.95 ($0.22M total) on 2026-11-02. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

Original reporting
SEC EDGAR · Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Venrock Healthcare Capital Partners XP, L.P., VHCP Management XP, LLC, Koh Bong Y, Shah Nimish P
Published Nov 4, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LYCA
Neutral
high confidence
Mentioned
$LYCA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LYCANeutralLow
01

Why it matters

The insider purchase is a positive signal but its small size limits immediate price impact.

02

Market read

Minor insider buying; unlikely to drive significant trading activity.

03

What to watch

Potential upcoming clinical data releases could amplify the significance of insider buying.

Relevance 5/10Novelty 4/10Timing: after-hours filing

Background

Form 4 filings provide primary disclosure of insider transactions. This filing reports a modest purchase by a venture capital affiliate.

Company-level read

Ticker impact

$LYCANeutralHigh confidence
Context

Venrock Healthcare Capital Partners III purchased 8,305 shares of Lycia Therapeutics at $26.95, increasing its stake to over 6.8 million shares.

Expected impact

slight upward pressure as the market prices in insider confidence

Evidence & confidence

The transaction size (~$224K) is modest for a public biotech; while insider buying is positive, the amount is unlikely to move the stock significantly.

Market effects

Minimal effect on the broader biotech sector.

No notable regional impact.

Limited to investors tracking insider activity.

Counterpoint

The purchase may be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Lycia Therapeutics, Inc.

    Biotech company developing therapies for rare diseases.

  • Venrock Healthcare Capital Partners III, L.P.

    Venture capital fund affiliated with Venrock.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

$LYCAHighAI 9/10

Lycia Therapeutics raises $365M in upsized Nasdaq IPO

Lycia Therapeutics (LYCA) raised $365.1M in its Nasdaq IPO, selling 20.29M shares at $18 each, including underwriters' options. The biotech firm focuses on therapeutics for autoimmune and allergic diseases, with lead candidates LCA-0061 and LCA-0321. The offering was managed by Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities, with LifeSci Capital as a passive manager.